HR2P Peptide Efficacy Against Porcine Deltacoronavirus

HR2P peptide exhibited an in vitro EC50 of 6.65 μM against porcine deltacoronavirus. The dataset likely contains results from antiviral efficacy, molecular docking, and pharmacokinetic analyses conducted by Yixiao Liang, uploaded to figshare in May 2026. The data describes a potential broad-spectrum therapeutic candidate.

Use Cases

• Evaluate antiviral peptide efficacy based on EC50 values mentioned in the description
• Analyze cross-species inhibitory activity based on results from avian, primate, and human cells
• Model pharmacokinetic profiles based on Cmax and administration route data
• Predict peptide binding sites based on molecular docking analysis against conserved structural sites

Strengths

• Includes a specific in vitro EC50 value of 6.65 μM
• Contains pharmacokinetic data with a reported Cmax of 194.6 μg/mL
• Describes efficacy against HR1-mutated variants and in piglet trials

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small (2.9 KB), indicating limited scope

Provenance

Source

figshare

Collection Method

Likely contains experimental data from peptide design, in vitro assays, molecular docking, and animal trials.

Freshness

Last updated 2026-05-08 06:29:42